| Author |
Title |
JournalName |
Year D |
| Click on Column Headers to Re-Sort The Current List |
| Johnson M, Hanson GR, Gib... |
Effect of MK-801 on the decrease in tryptophan hydroxylase induced by ... |
Eur J Pharmacol |
1989 |
| Finnegan KT, Skratt JJ, I... |
The N-methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prev... |
Neurosci Lett |
1990 |
| Dragunow M, Logan B, Lave... |
3,4-Methylenedioxymethamphetamine induces Fos-like proteins in rat bas... |
Eur J Pharmacol |
1991 |
| Johnson M, Bush LG, Gibb ... |
Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in n... |
Eur J Pharmacol |
1991 |
| Olney JW, Labruyere J, Wa... |
NMDA antagonist neurotoxicity: mechanism and prevention |
Science |
1991 |
| Farfel GM, Vosmer GL, Sei... |
The N-methyl-D-aspartate antagonist MK-801 protects against serotonin ... |
Brain Res |
1992 |
| Krogsgaard-Larsen P, Hans... |
Naturally-occurring excitatory amino acids as neurotoxins and leads in... |
Toxicol Lett |
1992 |
| Sosnowski M |
Pain management: physiopathology, future research and endpoints |
Support Care Cancer |
1993 |
| Rossner S, Schliebs R, Bi... |
Ibotenic acid lesion of nucleus basalis magnocellularis differentially... |
Brain Res |
1994 |
| Farfel GM, Seiden LS |
Role of hypothermia in the mechanism of protection against serotonergi... |
J Pharmacol Exp Ther |
1995 |
| Sprague JE, Nichols DE |
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-meth... |
J Pharmacol Exp Ther |
1995 |
| Finnegan KT, Taraska T |
Effects of glutamate antagonists on methamphetamine and 3,4-methylened... |
J Neurochem |
1996 |
| Seiden LS, Sabol KE |
Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possi... |
NIDA Res Monogr |
1996 |
| Popik P |
Facilitation of memory retrieval by the 'anti-addictive' alkaloid, ibo... |
Life Sci |
1996 |
| Fitzal S |
[Ketamine and neuroprotection. Clinical outlook] |
Anaesthesist |
1997 |
| Nikolajsen L, Hansen PO, ... |
Oral ketamine therapy in the treatment of postamputation stump pain |
Acta Anaesthesiol Sc... |
1997 |
| Nelson KA, Park KM, Robin... |
High-dose oral dextromethorphan versus placebo in painful diabetic neu... |
Neurology |
1997 |
| Kombian SB, Saleh TM, Fia... |
Ibogaine and a total alkaloidal extract of Voacanga africana modulate ... |
Brain Res Bull |
1997 |
| Lindefors N, Barati S, O'... |
Differential effects of single and repeated ketamine administration on... |
Brain Res |
1997 |
| Colado MI, Granados R, O'... |
Role of hyperthermia in the protective action of clomethiazole against... |
Br J Pharmacol |
1998 |
| Farber NB, Hanslick J, Ki... |
Serotonergic agents that activate 5HT2A receptors prevent NMDA antagon... |
Neuropsychopharmacol... |
1998 |
| Jones HE, Li H, Balster R... |
Failure of ibogaine to produce phencyclidine-like discriminative stimu... |
Pharmacol Biochem Be... |
1998 |
| Helsley S, Filipink RA, B... |
The effects of sigma, PCP, and opiate receptor ligands in rats trained... |
Pharmacol Biochem Be... |
1998 |
| Monks TJ, Ghersi-Egea JF,... |
Symposium overview: the role of glutathione in neuroprotection and neu... |
Toxicol Sci |
1999 |
| de Bruin NM, Ellenbroek B... |
Differential effects of ketamine on gating of auditory evoked potentia... |
Psychopharmacology B... |
1999 |
| Kolesnikov YA, Pasternak ... |
Peripheral blockade of topical morphine tolerance by ketamine |
Eur J Pharmacol |
1999 |
| Arvanov VL, Liang X, Russ... |
LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA recepto... |
Eur J Neurosci |
1999 |
| Berman RM, Cappiello A, A... |
Antidepressant effects of ketamine in depressed patients |
Biol Psychiatry |
2000 |
| West WB, Lou A, Pechersky... |
Antagonism of a PCP drug discrimination by hallucinogens and related d... |
Neuropsychopharmacol... |
2000 |
| Weinbroum AA, Rudick V, P... |
The role of dextromethorphan in pain control |
Can J Anaesth |
2000 |
| Russell BR, Laverty R |
Correlation between 5-HT content and uptake site density following (S)... |
Ann N Y Acad Sci |
2000 |
| Schatz DS, Kaufmann WA, S... |
3,4-Methylenedioxymetamphetamine (ecstasy) induces c-fos-like protein ... |
Synapse |
2000 |
| Shirayama Y, Hashimoto K,... |
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA i... |
Eur J Pharmacol |
2000 |
| Mansvelder HD, McGehee DS |
Long-term potentiation of excitatory inputs to brain reward areas by n... |
Neuron |
2000 |
| Russell BR, Laverty R |
The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-in... |
Pharmacology, Bioche... |
2001 |
| Baumann MH, Pablo J, Ali ... |
Comparative neuropharmacology of ibogaine and its O-desmethyl metaboli... |
Alkaloids Chem Biol |
2001 |
| Vollenweider FX, Geyer MA |
A systems model of altered consciousness: integrating natural and drug... |
Brain Res Bull |
2001 |
| Krupitsky EM, Burakov AM,... |
Attenuation of ketamine effects by nimodipine pretreatment in recoveri... |
Neuropsychopharmacol... |
2001 |
| Vollenweider FX |
Brain mechanisms of hallucinogens and entactogens |
Dialogues Clin Neuro... |
2001 |
| Gouzoulis-Mayfrank E, The... |
Effects of the hallucinogen psilocybin on covert orienting of visual a... |
Neuropsychobiology |
2002 |
| Gouzoulis-Mayfrank E, The... |
Effects of the hallucinogen psilocybin on covert orienting of visual a... |
Neuropsychobiology |
2002 |
| Jiang XR, Dryhurst G |
Inhibition of the alpha-ketoglutarate dehydrogenase and pyruvate dehyd... |
Chem Res Toxicol |
2002 |
| Gandolfi O, Gaggi R, Volt... |
The activation of serotonin receptors prevents glutamate-induced neuro... |
Pharmacol Res |
2002 |
| Baker AK, Hoffmann VL, Me... |
Dextromethorphan and ketamine potentiate the antinociceptive effects o... |
Pharmacol Biochem Be... |
2002 |
| Umbricht D, Vollenweider ... |
Effects of the 5-HT(2A) Agonist Psilocybin on Mismatch Negativity Gene... |
Neuropsychopharmacol... |
2002 |
| Lim DK |
Ketamine associated psychedelic effects and dependence |
Singapore Med J |
2003 |
| Zalish M, Lavie V |
Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and s... |
Vision Res |
2003 |
| Passie T, Karst M, Borsut... |
Effects of different subanaesthetic doses of (S)-ketamine on psychopat... |
J Psychopharmacol |
2003 |
| Darlington CL |
Dexanabinol: A novel cannabinoid with neuroprotective properties |
IDrugs |
2003 |
| Butelman ER, Harris TJ, K... |
The plant-derived hallucinogen, salvinorin A, produces kappa-opioid ag... |
Psychopharmacology (... |
2003 |
| Moyano S, Frechilla D, De... |
NMDA receptor subunit and CaMKII changes in rat hippocampus induced by... |
Psychopharmacology (... |
2004 |
| Kukanich B, Papich MG |
Plasma profile and pharmacokinetics of dextromethorphan after intraven... |
J Vet Pharmacol Ther |
2004 |
| Chen SL, Huang EY, Chow L... |
Dextromethorphan differentially affects opioid antinociception in rats |
Br J Pharmacol |
2005 |
| Grasshoff C, Gillessen T,... |
Ketamine reduces cholinergic modulated GABA release from rat striatal ... |
Toxicol Lett |
2005 |
| Ostroff R, Gonzales M, Sa... |
Antidepressant Effect of Ketamine During ECT |
Am J Psychiatry |
2005 |
| Lambe EK, Aghajanian GK |
Hallucinogen-Induced UP States in the Brain Slice of Rat Prefrontal Co... |
Neuropsychopharmacol... |
2005 |
| Narendran R, Frankle WG, ... |
Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketam... |
Am J Psychiatry |
2005 |
| Tang Y, Zou H, Strong JA,... |
Paradoxical effects of very low dose MK-801 |
Eur J Pharmacol |
2006 |
| Carliss RD, Radovsky A, C... |
Oral administration of dextromethorphan does not produce neuronal vacu... |
Neurotoxicology |
2007 |
| Maeng S, Zarate CA, Du J,... |
Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine:... |
Biol Psychiatry |
2007 |
| Camarasa J, Marimon JM, R... |
Memantine prevents the cognitive impairment induced by 3,4-methylenedi... |
Eur J Pharmacol |
2008 |
| Dinis-Oliveira RJ, Carval... |
Suicide by hanging under the influence of ketamine and ethanol |
Forensic Sci Int |
2010 |
| Reissig CJ, Carter LP, Jo... |
High doses of dextromethorphan, an NMDA antagonist, produce effects si... |
Psychopharmacology (... |
2012 |
| Sanacora G, Smith MA, Pat... |
Lanicemine: a low-trapping NMDA channel blocker produces sustained ant... |
Mol Psychiatry |
2013 |
| de Sousa Fernandes Perna ... |
Memory and mood during MDMA intoxication, with and without memantine p... |
Neuropharmacology |
2014 |
| Nagele P, Duma A, Kopec M... |
Nitrous Oxide for Treatment-Resistant Major Depression: a Proof-of-Con... |
Biological Psychiatr... |
2014 |
| Van Hout MC, Hearne E |
Word of mouse: indigenous harm reduction and online consumerism of the... |
J Psychoactive Drugs |
2015 |
| McLaughlin G, Morris N, K... |
Test purchase, synthesis, and characterization of 2-methoxydiphenidine... |
Drug Test Anal |
2015 |
| Bäckberg M, Beck O, Helan... |
Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO... |
Clin Toxicol (Phila) |
2015 |
| Zorumski CF, Nagele P, Me... |
Treatment-Resistant Major Depression: Rationale for NMDA Receptors as ... |
Front Psychiatry |
2015 |
| Litjens RP, Brunt TM |
How toxic is ibogaine? |
Clin Toxicol (Phila) |
2016 |
| Das RK, Tamman A, Nikolov... |
Nitrous oxide speeds the reduction of distressing intrusive memories i... |
Psychol Med |
2016 |
| Wallach J, Kang H, Colest... |
Pharmacological Investigations of the Dissociative 'Legal Highs' Diphe... |
PLoS One |
2016 |
| Kang H, Park P, Bortolott... |
Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor ... |
Neuropharmacology |
2017 |
| Heal DJ, Gosden J, Smith ... |
Evaluating the abuse potential of psychedelic drugs as part of the saf... |
Neuropharmacology |
2018 |
| Ingram R, Kang H, Lightma... |
Some distorted thoughts about ketamine as a psychedelic and a novel hy... |
Neuropharmacology |
2018 |
| Bertron JL, Seto M, Linds... |
DARK Classics in Chemical Neuroscience: Phencyclidine (PCP) |
ACS Chem Neurosci |
2018 |
| Botanas CJ, de la Peña JB... |
Methoxetamine: A foe or friend? |
Neurochem Int |
2019 |
| Martial C, Cassol H, Char... |
Neurochemical models of near-death experiences: a large-scale study ba... |
Conscious Cogn |
2019 |
